Drug intelligence / Profile preview

Alpha fetoprotein adenoviral vector vaccine

Development stage: Phase 2
Lead developer: UCLA Jonsson Comprehensive Cancer Center
Modality: Gene Therapies, Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

Alpha fetoprotein adenoviral vector vaccine is an investigational cancer vaccine that uses a prime-boost strategy combining AFP DNA plasmids and an AFP-expressing adenoviral vector. It is designed to stimulate immune responses against alpha fetoprotein (AFP), an oncofetal antigen overexpressed by many hepatocellular cancers. The vaccine aims to activate both CD8+ and CD4+ T cells against AFP-expressing tumor cells, potentially preventing or delaying recurrence of hepatocellular carcinoma after primary treatment.

Targets

AFP (Alpha-fetoprotein)Neuraminidase

Beyond the preview

Go deeper on Alpha fetoprotein adenoviral vector vaccine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Alpha fetoprotein adenoviral vector vaccine.

Explore the full profile